Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion Injury

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Ischemia/reperfusion (I/R) injury is a significant clinical problem.
• Activating transcription factor 6 (ATF6) is a key regulator of the unfolded protein response (UPR) and can be protective in I/R injury.
• Selective activation of ATF6 under disease conditions remains a challenge.

Purpose of the Study:

• To design and synthesize a reactive oxygen species (ROS)-activatable prodrug for targeted delivery of an ATF6 activator.
• To evaluate the prodrug's activation mechanism and biological efficacy in protecting against oxidative stress and I/R injury.

Main Methods:

• Synthesis of a novel ROS-activatable prodrug (compound 1) and a non-activatable control.
• Investigation of peroxide-mediated activation and metabolic stability using cytochrome P450 enzymes (e.g., Cyp1A2).
• Biological evaluation in primary cardiomyocytes subjected to peroxide stress and simulated I/R injury.

Main Results:

• The ROS-activatable prodrug selectively releases the active ATF6 activator in the presence of peroxides.
• The prodrug demonstrated protection against peroxide-induced toxicity in cardiomyocytes.
• Enhanced cell viability was observed following simulated I/R injury using the prodrug.

Conclusions:

• The developed ROS-activatable prodrug enables targeted ATF6 activation under disease-specific conditions.
• This strategy holds therapeutic potential for I/R injury and other protein misfolding diseases.
• Localized, stress-responsive signaling pathway activation is a promising therapeutic modality.